Precigen, Inc.
MUC16 specific chimeric antigen receptors and uses thereof
Last updated:
Abstract:
Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders.
Status:
Grant
Type:
Utility
Filling date:
4 Jun 2019
Issue date:
3 May 2022